MedTrace Logo

Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia

NCT00969891 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2011-08-25

No results posted yet for this study

Summary

The present study is not hypothesis driven but will explore the ability of pharmacokinetic-pharmacodynamic modelling to predict optimal dosage of the chemotherapeutic drugs used in therapy in adult patients with acute myeloid leukemia.

Conditions

Interventions

OTHER

PK-PD analysis

The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Herlev Hospital

    collaborator OTHER

  • Mikkel Krogh-Madsen

    lead OTHER

Principal Investigators

  • Ove J Nielsen, MD · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Completion
2011-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00969891 on ClinicalTrials.gov